Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? - Test2 - elhamkhani - TriplyDB

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

http://www.wikidata.org/entity/Q26795742

about

Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use Treatment pathway of bone sarcoma in children, adolescents, and young adults Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases.STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group.Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1.Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells.

P2860

Q28068930-150A6144-7123-4DC5-9E95-D07269E97FB0 Q33835657-91846529-B674-4931-83FE-CA1ACC5C9BD8 Q37565298-87CFD47F-6F2C-48C9-BF24-709C1C6A013D Q37662264-08B48435-C083-48E8-B195-B0C7216C4D07 Q37718554-A1ACEE27-041F-4123-AAC8-D5D08F0ED2C2 Q48114539-17F79DA3-4189-44B0-87BD-F3CE51783941 Q50091965-0E855CB4-3075-44CB-A725-E059867483AC Q55109900-67F5D358-6FDC-4964-A32B-781FAE2B14AA

P2860

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

http://www.wikidata.org/entity/Q26795742

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

@ast

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

@en

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

@nl

type

label

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

@ast

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

@en

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

@nl

prefLabel

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

@ast

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

@en

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

@nl

P1433

Q26795742-26FD056F-8F88-4870-B54C-88F29A70BC6E

P1476

Q26795742-819387A6-EEF5-4E90-B1E8-92DE9E2A1FF1

P2093

Q26795742-87D94C10-B177-4758-9CCD-F3CE74EEC3BB

P2860

Q26795742-03386522-4C26-49B6-B069-F5E7C612AAC2

Q26795742-035690D5-96B6-4120-8B99-D005E4F7BB45

Q26795742-158F7BFC-4475-4E1B-AED5-E12D37769824

Q26795742-15F5930F-23FE-47EF-9E55-14C4FF63A535

Q26795742-17CB6648-B1C6-440E-8AE1-B6D1FEBA2DB0

Q26795742-1FF27AD1-BFC0-4F17-AC3B-2691A5CC382C

Q26795742-21C2D98C-38A8-4003-BD41-76FDFC3AEF3A

Q26795742-29031579-39E8-4B54-B08D-04ECFF500059

Q26795742-2A704DC8-6515-4AF1-A6EF-1DB874858596

Q26795742-2BCBA536-298C-49B1-909E-BA10A55BF290

P2888

Q26795742-A229A81F-8696-485B-A35F-10D2618E2942

P304

Q26795742-0988DF5E-6971-4C83-902F-F0ECC486258E

P31

Q26795742-E8AEB9CC-CE62-4B6A-BD98-98EFC83CCF82

P3181

Q26795742-BC5AF392-9A41-4AF8-BEDB-E28A4243E1B9

P356

Q26795742-3ED21A16-ED6E-45E1-98AE-8DE4A287B4A5

P407

Q26795742-E2F56F07-F68E-4E6E-B3FB-E7272B6E2BDB

P433

Q26795742-5557E613-64C2-4F82-B10A-BDC0D624DBE6

P478

Q26795742-FAF8B611-D587-4A1E-9523-C277550CD5F1

P50

Q26795742-41BFD782-190A-4857-B29D-37873D78F777

P577

Q26795742-3B5FF922-5E33-444B-A895-429E9130BB29

P5875

Q26795742-31F5E364-A1A6-4AD2-A882-AED1B6DBAC5D

P6179

Q26795742-4AD6B2A4-3122-43E2-9094-B2C7DB800B49

P698

Q26795742-FB8A5281-F6B2-4E23-90FD-1084C8AEF66F

P932

Q26795742-63B2F6B3-478B-4083-B466-805D90E1BD95

P3181

P356

S13569-015-0035-X

P1433

Clinical Sarcoma Research

P1476

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

@en

P2093

Lars M Wagner

http://www.w3.org/2001/XMLSchema#string

P2860

Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy

Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts

Systematic identification of genomic markers of drug sensitivity in cancer cells

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine.

Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.

Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study

Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.

Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.

P2888

s13569-015-0035-x

P304

20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3616335

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S13569-015-0035-X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281483396

http://www.w3.org/2001/XMLSchema#string

P6179

1027288949

http://www.w3.org/2001/XMLSchema#string

P698

26322224

http://www.w3.org/2001/XMLSchema#string

P932

4552408

http://www.w3.org/2001/XMLSchema#string